Latest Breaking News On - Eugenia litz - Page 8 : comparemela.com

ADC Therapeutics SA: ADC Therapeutics Announces Voluntary Pause of Enrollment in the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients

ADC Therapeutics SA: ADC Therapeutics Announces Voluntary Pause of Enrollment in the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Twitterand linkedinEugenia litzNicole rileyData monitoring committeeCompany annual report on formEuropean medicines agencyExchange commissionDrug administrationEuropean commissionAmeet mallikChief executive officerStudy entryEmergent adverse eventsFatal outcomeEmergent gradeMediastinal disorders

ADC Therapeutics Announces Evolution of Board of Directors

Strengthens the Board with the election of Robert W. Azelby as director

New jerseyUnited statesCity ofUnited kingdomEugenia litzChris martinLausanne biopMichael forerJacques theurillatRobertw azelbyStephen evans frekeMary ann ondishHarvard business schoolMitsubishi tanabe pharma corporationOverland pharmaceuticalsUniversity of virginia

ADC Therapeutics Announces Updated LOTIS-2 Results Demonstrating Durable, Long-Term Responses of ZYNLONTA® in Relapsed/Refractory DLBCL

ADC Therapeutics Announces Updated LOTIS-2 Results Demonstrating Durable, Long-Term Responses of ZYNLONTA® in Relapsed/Refractory DLBCL
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesCity ofUnited kingdomNew jerseyMehdi hamadaniLoncastuximab tesirinePaolof caimiMohamed zakiParco cianiEugenia litzMary ann ondishKathryna logronioLausanne biopJohn wileyEuropean hematology associationExchange commission

ADC Therapeutics Announces Updated LOTIS-2 Results Demonstrating Durable, Long-Term Responses

LAUSANNE, Switzerland, June 09, 2023 (GLOBE NEWSWIRE) ADC Therapeutics SA (NYSE: ADCT) today announced updated results from LOTIS-2, the pivotal Phase 2 clinical trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in

United statesCity ofUnited kingdomNew jerseyKathryna logronioPaolof caimiMehdi hamadaniParco cianiLausanne biopEugenia litzMary ann ondishLoncastuximab tesirineJohn wileyMohamed zakiEuropean hematology associationCollege of wisconsin

ADC Therapeutics Announces Updated LOTIS-2 Results

Data being presented at the EHA 2023 Hybrid Congress will also be highlighted in an encore oral presentation at 17-ICML.

City ofUnited kingdomNew jerseyUnited statesLausanne biopMohamed zakiJohn wileyParco cianiMary ann ondishPaolof caimiEugenia litzLoncastuximab tesirineKathryna logronioMehdi hamadaniSons incEuropean commission